Amundi
CPRX

Amundi’s Catalyst Pharmaceutical CPRX Stock Holding History

Amundi’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$779K Buy
31,463
+12,778
+68% +$304K ﹤0.01% 1373
2025
Q4 		$436K Sell
18,685
-1,845
-9% -$41.1K ﹤0.01% 1528
2025
Q3 		$426K Buy
20,530
+1,843
+10% +$37.9K ﹤0.01% 1372
2025
Q2 		$401K Sell
18,687
-26,444
-59% -$624K ﹤0.01% 1432
2025
Q1 		$1.09M Sell
45,131
-11,478
-20% -$258K ﹤0.01% 1310
2024
Q4 		$1.29M Buy
56,609
+36,968
+188% +$794K ﹤0.01% 1339
2024
Q3 		$394K Buy
19,641
+2,905
+17% +$53.9K ﹤0.01% 1490
2024
Q2 		$256K Sell
16,736
-2,926
-15% -$45.6K ﹤0.01% 1519
2024
Q1 		$302K Buy
19,662
+6,503
+49% +$98K ﹤0.01% 1542
2023
Q4 		$201K Buy
13,159
+616
+5% +$8.42K ﹤0.01% 1631
2023
Q3 		$160K Buy
12,543
+1
+0% +$13 ﹤0.01% 1650
2023
Q2 		$160K Buy
+12,542
New +$180K ﹤0.01% 1663

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Amundi's CPRX Position: Q1 2026 in Review

Amundi increased its Catalyst Pharmaceutical (CPRX) stake by 68% in Q1 2026, buying an estimated $304K and bringing the position to 31,463 shares worth $779K. The position accounts for ﹤0.01% of the portfolio, ranked #1373.

Amundi first reported a position in CPRX in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.29M in Q4 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Amundi held 31,463 shares of Catalyst Pharmaceutical worth $779K as of Q1 2026.
  • Amundi bought 12,778 Catalyst Pharmaceutical shares in Q1 2026, an estimated $304K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1373 holding.
  • Amundi first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 12 quarters since.
  • Amundi's Catalyst Pharmaceutical position peaked at $1.29M in Q4 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.